Home » Ambrilia Starts Prostate Cancer Trial
Ambrilia Starts Prostate Cancer Trial
Ambrilia Biopharma has initiated a Phase I/II trial for goserelin in patients with hormone-sensitive prostate cancer.
The product is an injectable formulation of the three-month release version of Zoladex, a luteinizing hormone-releasing hormone analogue indicated for hormone-sensitive prostate cancer as well as gynecological indications such as fibro-myomas and endometriosis, Ambrilia said.
The multicenter study will assess the hormonal efficacy, pharmacokinetics and safety of the drug.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May